Novo Nordisk’s weight-loss medication Wegovy (semaglutide) was approved in Japan in March. While it skipped the May round of reimbursement listing, physicians eagerly await the arrival of what would be the first new obesity drug in three decades. Other companies…
HOME > ACADEMIA
ACADEMIA
- Keep Public Funding for COVID Drugs to Get through This Winter: Academic Societies
May 25, 2023
- Osaka University Completes Transplants of iPS Cell-Derived Cardiac Cell Sheet
May 22, 2023
- OB/GYN Society Aims for Early Use of Oral Abortion Pill at Clinics without Beds
May 12, 2023
- Lung Cancer Trial Aborted as 11 Die after Opdivo-Yervoy Therapy: NCC, JCOG
May 1, 2023
- More Japan-Specific Data, Stable Supplies of Pfizer’s Stelues Needed amid Syphilis Surge: Specialist
April 27, 2023
- Abortion Pill Is Beneficial as New Option, but Don’t See It as Easy Solution: OB/GYN Association Chair
April 20, 2023
- National CV Center Running Crowdfunding Project to Continue Fibrinolytic Trial in Japan
April 19, 2023
- Wegovy First Med to Meet Guidelines Criteria for Obesity Drug Development
March 30, 2023
- Obesity Med Wegovy Could Be “Ace in the Hole”, Should Avoid Fate of Oblean: KOL
March 30, 2023
- MHLW Panel OKs Research Report That Could Set Stage for Gene Profiling Before 1st-Line Cancer Therapy
March 15, 2023
- Japan’s Antimicrobial Use in 2022 Levels Off YOY, Down 31.5% from 2013
March 10, 2023
- Probe Panel Recognizes Professor’s COI over Glactiv Scandal, but Doubts Whether It Constitutes Bribery
February 24, 2023
- Investigators Doubt Mitsubishi’s Trial Data on Muse Cell Therapy; Program Aborted without Notice
February 17, 2023
- 80% of Medical Institutions Say Reimbursement Fees “Essential” to Introduce Formularies: Study
February 8, 2023
- Over Half of Pregnant Women Shun COVID Jab for Side Effect Fears: Survey
December 6, 2022
- Lewy Body Dementia Specialist Sees Aricept Approval Modification as Positive Move
December 6, 2022
- Building Delivery Scheme for Disease-Modifying Drugs for Alzheimer’s Is Critical: Academic Societies
November 30, 2022
- Obesity Society to Highlight Proper Use of Semaglutide If Label Expanded
November 29, 2022
- Japan Infectious Diseases Association Updates Guidelines after Xocova Approval
November 25, 2022
- Academic Societies Warn against Hoarding Meropenem as Supply Crunch Intensifies
November 21, 2022
ページ
President Joe Biden enacted the Inflation Reduction Act (IRA) on August 16, 2022, significantly affecting Medicare prescription drug coverage and introducing targeted changes to Medicaid, the Children’s Health Insurance Program, and private health insurance. In January 2023, the Centers for…
Japan’s health ministry on April 27 presented an outline of a report to be compiled next month by its key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…